Prevention of the Complications of Hemophilia Thru Hemophilila Treatment Centers

通过血友病治疗中心预防血友病并发症

• 批准号: 7487535
• 负责人: Christopher E Walsh
• 金额: $ 68.91万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-30 至 2011-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7487535
• 关键词: Prevention; Complications; Hemophilia; Thru; Hemophilila

DESCRIPTION (provided by applicant): The overall objective of this application is to prevent the complications of hemophilia and bleeding disorders through the expansion and acquisition of clinical data sets. These data sets will include both disease-specific and general-health related information. The data acquired will be used for proactive implementation of prevention programs throughout the network of multidisciplinary comprehensive Hemophilia Treatment Centers (HTC) throughout the United States. HTC's are designed to treat patients with hemophilia A and B, von Willebrand Disease and rare factor deficiencies. Utilizing the comprehensive care model, therapeutic interventions based on previously collected data and changes in therapy based on new research continues to enhance the care of the bleeding disorders community. Chronic genetic disorders often require complex and multidisciplinary care for optimal diagnosis, treatment and management. The consequences of bleeding disorders include severe medical, financial, vocational, psychological and familial repercussions when the condition is not properly managed. The lack of proper treatment has general public health consequences such as increased costs of care caused by increased hospital and emergency utilization and patient disability that may require welfare and other government entitlements. A regional approach to planning, coordination and allocation of funds is vital to ensure that services are available to treat this and other complicated bleeding disorders in Region II, New York, New Jersey, Puerto Rico and the US Virgin Islands. The proposed program will continue a national network of federally funded HTCs organized through 12 regional core centers and funded by the CDC. Aim 1: To provide comprehensive prevention services to persons with bleeding disorders directed at attaining and measuring specific outcomes through research and surveillance aimed at reducing complications using a multidisciplinary approach. Under this aim we propose to expand the cohort through continued recruitment and observation individuals with genetic bleeding disorders including hemophilia A and B, von Willebrand disease, rare bleeding disorders and women with bleeding disorders; and expand the current Universal Data and Serum Specimen Collection System (UDC) database to collect additional relevant data related to women's issues in coagulation, rare bleeding disorders, prophylaxis, factor utilization, inhibitors, genetic mutations, and other important clinical outcomes. We plan to design and pilot additional studies aimed at further characterizing the bleeding disorders population through the expanded access to a) gene-based diagnosis and b) more precise definition of the biochemical phenotype (e.g. global assays) with the ultimate goal of genotype - phenotype correlation; utilize the UDC BMI data to evaluate the cost impact on the health care system from conditions with weight-based dosing; test interventions that could facilitate weight loss; and design and pilot a study to evaluate effects of rising annual out- of-pocket expenses and co-payments on the use of elective/preventive services provided by the HTC. Aim 2: Maintain A Regional Network Of Comprehensive Prevention Services Through Hemophilia Treatment Centers to Persons With Hemophilia and Related Disorders Including Women, Minorities and the Underserved. Under this broad aim we will lay out our comprehensive, culturally sensitive, family-centered care services and their expansion, our communication within the region and administrative mechanisms. These include outreach and education, orientation and training programs, maintenance of appropriate management and evaluation systems, maintenance of a prevention evaluation network to assess the efficacy of prevention services by increasing the capacity for data collection, moving from paper to electronic and our participation in the coordinating committee. Our plan as stated will promote health and quality of life by preventing and controlling disease, injury, and disability. Many of our aims will facilitate reducing health disparities and accelerate the adoption of health behaviors while improving prevention effectiveness through cost-based studies. Some aims will be directly transferable to other chronic disease populations in the general public such as the evaluation of obesity and menorrhagia.

描述（由申请人提供）：本申请的总体目标是通过扩展和采集临床数据集来预防血友病和出血性疾病的并发症。这些数据集将包括特定疾病和一般健康相关信息。获得的数据将用于在美国多学科综合血友病治疗中心（HTC）网络中积极实施预防计划。HTC设计用于治疗血友病A和B、血管性血友病和罕见因子缺乏症患者。利用综合护理模式，基于先前收集的数据的治疗干预和基于新研究的治疗变化继续加强出血性疾病社区的护理。慢性遗传性疾病往往需要复杂和多学科的护理，以实现最佳诊断、治疗和管理。出血性疾病的后果包括严重的医疗，经济，职业，心理和家庭的影响时，条件是不适当的管理。缺乏适当的治疗会对公众健康产生普遍的影响，例如，医院和急诊使用率的增加导致护理费用增加，病人残疾可能需要福利和其他政府应享权利。规划、协调和分配资金的区域方法对于确保在第二区、纽约、新泽西、波多黎各和美属维尔京群岛提供治疗这种和其他复杂出血性疾病的服务至关重要。拟议的计划将继续通过12个区域核心中心组织并由疾病预防控制中心资助的联邦资助的国家HTCs网络。目标1：为出血性疾病患者提供全面的预防服务，旨在通过研究和监测实现和衡量具体成果，旨在采用多学科方法减少并发症。在此目标下，我们建议通过持续招募和观察患有遗传性出血性疾病（包括血友病A和B、血管性血友病、罕见出血性疾病和女性出血性疾病）的个体来扩大队列;并扩展当前的通用数据和血清标本采集系统（UDC）数据库，以收集与凝血、罕见出血性疾病、预防、因子利用、抑制剂、基因突变和其他重要临床结局。我们计划设计和试点其他研究，旨在通过扩大a）基于基因的诊断和B）更精确的生化表型定义，进一步表征出血性疾病人群（例如，全球测定），最终目标是基因型-表型相关性;利用UDC BMI数据评估基于体重给药的条件对医疗保健系统的成本影响;测试可以促进减肥的干预措施;设计并试点一项研究，以评估每年自付费用和共同支付对使用HTC提供的选择/预防服务的影响。目标二：通过血友病治疗中心维持一个区域综合预防服务网络，向血友病和相关疾病患者，包括妇女、少数民族和得不到充分服务的人提供服务。在这一广泛目标下，我们将制定全面的、文化敏感的、以家庭为中心的护理服务及其扩展，我们在区域内的沟通和行政机制。这些措施包括推广和教育、指导和培训方案、维持适当的管理和评价系统、维持一个预防评价网络，以通过提高数据收集能力、从纸面转向电子以及我们参与协调委员会来评估预防服务的效力。如前所述，我们的计划将通过预防和控制疾病、伤害和残疾来促进健康和生活质量。我们的许多目标将有助于减少健康差距，加快健康行为的采用，同时通过基于成本的研究提高预防效果。一些目标将直接转移到其他慢性疾病人群中，如肥胖和月经过多的评估。